Also known as: CA 19-9, CA19-9
PancreaSure detected advanced PDAC with 87.9% sensitivity and 97.7% specificity, outperforming CA19-9 alone. PanMETAI, an AI metabolomics model, achieved AUC 0.99 in training and 0.93 in external validation for early PDAC detection.
A new four-marker blood test detects pancreatic cancer with 91.9% accuracy across all stages and 87.5% accuracy for early-stage disease. The test combines two newly identified proteins with existing biomarkers and can differentiate cancer from non-cancerous conditions. While promising for pancreatic cancer, most cancers still cannot be reliably diagnosed with blood tests alone.
A 30-year-old female with stage IV gallbladder adenocarcinoma achieved complete metabolic resolution of metastases after three cycles of pembrolizumab, gemcitabine, and cisplatin, despite presenting without traditional risk factors.
